» Articles » PMID: 22276960

Physician Experience and Rates of Plasma HIV-1 RNA Suppression Among Illicit Drug Users: an Observational Study

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2012 Jan 27
PMID 22276960
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite the availability of antiretroviral therapy (ART), suboptimal treatment outcomes have been observed among HIV-seropositive illicit drug users. As there is an urgent need to improve responses to antiretroviral therapy among this population, we undertook this study to evaluate the role of physician experience on rates of plasma HIV-1 RNA suppression following initiation of ART.

Methods: Using data from a community-recruited cohort of HIV-positive illicit drug users, we used Cox proportional hazards regression to model the time to plasma viral HIV RNA < 500 copies/mL among antiretroviral-naïve subjects initiating ART. Physician experience was defined as a continuous variable measured per 100 HIV-infected patients previously enrolled in the province-wide HIV treatment registry by that physician at the time a patient was enrolled.

Results: Between May 1996 and December 2008, 267 individuals initiated ART among whom 227 (85%) achieved a plasma HIV RNA < 500 copies/mL during the study period. In a multivariate analysis, greater physician experience was independently associated with higher rates of plasma HIV RNA suppression (adjusted hazard ratio [AHR] = 1.17, 95% confidence interval [CI]: 1.03-1.34) after adjustment for adherence to ART. Other factors associated with viral suppression included engagement in methadone maintenance therapy (AHR = 1.61, 95% CI: 1.23-2.09), ≥ 95% adherence to ART (AHR = 2.42, 95% CI: 1.80-3.26), baseline CD4 count (AHR = 0.89, 95% CI: 0.83-0.96) and baseline plasma HIV-1 RNA (AHR = 0.65, 95% CI: 0.53-0.81).

Conclusions: In this setting of universal HIV/AIDS care, illicit drug users with more experienced physicians exhibited faster rates of plasma viral load suppression. These findings argue for specialized services to help optimize HIV treatment outcomes among this population.

Citing Articles

Prevalence and Correlates of Heavy Alcohol use among People Living with HIV who use Unregulated Drugs in Vancouver, Canada.

Hui J, Reddon H, Fairbairn N, Choi J, Milloy M, Socias M AIDS Behav. 2024; 28(7):2427-2437.

PMID: 38662276 DOI: 10.1007/s10461-024-04341-y.


COVID-19 vaccination among young people who use drugs in Vancouver, Canada.

McAdam E, Hayashi K, Barker B, Reddon H, Choi J, Kerr T Vaccine. 2024; 42(4):864-870.

PMID: 38225183 PMC: 10922946. DOI: 10.1016/j.vaccine.2024.01.003.


Differential Role of Psychosocial, Health Care System and Neighborhood Factors on the Retention in HIV Care of Women and Men in the Ryan White Program.

Trepka M, Sheehan D, Dawit R, Li T, Fennie K, Gebrezgi M J Int Assoc Provid AIDS Care. 2020; 19:2325958220950087.

PMID: 32815475 PMC: 7444131. DOI: 10.1177/2325958220950087.


Sustained HIV viral suppression among men who have sex with men in the Miami-Dade County Ryan White Program: the effect of demographic, psychosocial, provider and neighborhood factors.

Sheehan D, Dawit R, Gbadamosi S, Fennie K, Li T, Gebrezgi M BMC Public Health. 2020; 20(1):326.

PMID: 32169065 PMC: 7069036. DOI: 10.1186/s12889-020-8442-1.


Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators.

Bansi-Matharu L, Rodriguez Loria G, Cole S, Mugerwa H, Vecino I, Lundgren J AIDS. 2019; 33(8):1385-1390.

PMID: 30932953 PMC: 6546512. DOI: 10.1097/QAD.0000000000002210.


References
1.
Gross R, Yip B, Lo Re 3rd V, Wood E, Alexander C, Harrigan P . A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006; 194(8):1108-14. DOI: 10.1086/507680. View

2.
Wood E, Hogg R, Yip B, Harrigan P, OShaughnessy M, Montaner J . Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?. AIDS. 2003; 17(5):711-20. DOI: 10.1097/00002030-200303280-00009. View

3.
Press N, Tyndall M, Wood E, Hogg R, Montaner J . Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2003; 31 Suppl 3:S112-7. DOI: 10.1097/00126334-200212153-00005. View

4.
Wood E, Kerr T, Zhang R, Guillemi S, Palepu A, Hogg R . Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. HIV Med. 2008; 9(7):503-7. DOI: 10.1111/j.1468-1293.2008.00582.x. View

5.
Moss A, Hahn J, Perry S, Charlebois E, Guzman D, Clark R . Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis. 2004; 39(8):1190-8. DOI: 10.1086/424008. View